乳腺癌细胞的高通量蛋白质组学：聚焦于傅里叶变换离子回旋共振质谱（FTICR-MS）

High-throughput proteomics of breast carcinoma cells: a focus on FTICR-MS.

作者信息

Umar Arzu, Jaremko Malgorzata, Burgers Peter C, Luider Theo M, Foekens John A, Pasa-Tolic Ljiljana

机构信息

University Medical Center Rotterdam, Josephine Nefkens Institute, Laboratory of Genomics & Proteomics in Breast Cancer, Department of Medical Oncology, Dr. Molewaterplein 50, Be 430c, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.

出版信息

Expert Rev Proteomics. 2008 Jun;5(3):445-55. doi: 10.1586/14789450.5.3.445.

DOI:10.1586/14789450.5.3.445

PMID:18532912

Abstract

Discovery of better biomarkers for diagnosis, prognosis and therapy-response prediction is the most critical task of a scientific quest aimed at developing novel, tailormade therapies for patients with cancer. Consequently, a proteome-wide analysis, in addition to genomic studies, is an absolute requirement for a complete functional understanding of tumor biology. Ultra-sensitive, high-performance Fourier-transform ion-cyclotron resonance (FTICR) mass spectrometry (MS) currently holds an important role in fulfilling the demands of biomarker discovery. In this review, we describe the applicability of FTICR-MS for breast cancer proteomics, particularly for the analysis of complex protein mixtures obtained from a limited number of cells typically available from clinical specimens.

摘要

发现用于诊断、预后评估和治疗反应预测的更好生物标志物，是旨在为癌症患者开发新型定制疗法的科学探索中最关键的任务。因此，除了基因组研究之外，进行全蛋白质组分析对于全面了解肿瘤生物学功能是绝对必要的。超灵敏、高性能的傅里叶变换离子回旋共振（FTICR）质谱（MS）目前在满足生物标志物发现的需求方面发挥着重要作用。在本综述中，我们描述了FTICR-MS在乳腺癌蛋白质组学中的适用性，特别是用于分析从临床标本中通常可获得的有限数量细胞中获取的复杂蛋白质混合物。